The Conversation (0)
InMed Pharmaceuticals announced the filing of a provisional patent application pertaining to the Company’s proprietary biosynthesis program for the manufacture of cannabinoids that are identical to those found in nature.
InMed Pharmaceuticals (CSE:IN; OTCQB:IMLFF) announced the filing of a provisional patent application pertaining to the Company’s proprietary biosynthesis program for the manufacture of cannabinoids that are identical to those found in nature.
As quoted in the press release:
The patent application, once converted into an international Patent Cooperation Treaty (PCT) application and pursued in key jurisdictions throughout the world, will provide significant commercial protection for InMed’s E. coli-based expression system to manufacture any of the 90+ cannabinoid compounds that may have a medical impact on important human diseases.
This will be the first in a series of patent applications directed to various aspects of the Company’s biosynthesis program. In particular, these applications focus on the superior nature of E. coli-based expression systems over other approaches; gene optimization for maximizing the production of cannabinoids and related compounds; and other proprietary developments and data. The company will actively convert this and subsequent provisional patents into national-stage filings in all major commercial jurisdictions, in due course.
Click here to read the full press release.
Source: www.newswire.ca
